Monitor for continued insider selling in the next 30 days. Given the size of the monetization (~0.018% of market cap), this is not yet alarmingly large, but the concentration of activity in the CEO raises caution. Check upcoming Form 4s for any further dispositions or changes in holdings.
Price Chart
Executive Summary
United Therapeutics CEO Martine Rothblatt conducted a series of derivative exercises and open-market sales over the past week, including over $2.2 million in share sales. Director Malcolm Jan and Director Judy Olian also sold smaller amounts. The majority of the economic activity stems from Rothblatt monetizing previously held options.
Key Financial Metrics
Key Facts
- CEO Martine Rothblatt sold 2,100 shares in open-market transactions totaling ~$1.13 million over three days (March 12–16).
- Rothblatt exercised 38,000 derivative securities across four transactions, with 19,000 at $0 cost and 19,000 at $146.03 strike price, unlocking ~$2.77 million in value.
- Total open-market sales by insiders in the cluster: 2,795 shares, ~$1.43 million.
- Directors Malcolm Jan and Judy Olian sold 45 and 200 shares respectively for $24K and $107K — small relative to CEO activity.
- All transactions occurred between March 12–17 at prices between $532–$535/share.
Financial Impact
$1.43 million in open-market sales by insiders, with $2.77 million in option exercises. Total insider monetization: ~$4.2 million.
Risk Factors
- Sustained insider selling could signal lack of confidence in near-term prospects.
- Option exercises followed by sales may indicate profit-taking ahead of potential headwinds.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (9 trades, 7d window) | cluster-UTHR-1773781010511 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $500.35 $497.31 | ▼ −0.61% | ▼ −2.72% | $571.38 (+14.20%) |
Sep 11, 2026 21d ago | Insider Cluster | $497.11 $494.63 | ▼ −0.50% | ▼ −0.28% | $571.38 (+14.94%) |
Sep 10, 2026 22d ago | Insider Cluster | $503.86 $497.27 | ▼ −1.31% | ▼ −0.81% | $571.38 (+13.40%) |
Sep 9, 2026 23d ago | Insider Cluster | $506.82 $498.48 | ▼ −1.65% | ▼ −0.99% | $571.38 (+12.74%) |
Sep 4, 2026 28d ago | Insider Cluster | $487.61 $502.70 | ▲ +3.09% | ▲ +4.30% | $571.38 (+17.18%) |
Sep 3, 2026 29d ago | Insider Cluster | $488.16 $497.11 | ▲ +1.83% | ▲ +2.98% | $571.38 (+17.05%) |
Aug 28, 2026 5w ago | Insider Cluster | $515.46 $487.61 | ▼ −5.40% | ▼ −5.51% | $571.38 (+10.85%) |
Aug 27, 2026 5w ago | Insider Cluster | $527.91 $492.02 | ▼ −6.80% | ▼ −6.03% | $571.38 (+8.23%) |
Aug 26, 2026 5w ago | Insider Cluster | $516.68 $492.02 | ▼ −4.77% | ▼ −4.65% | $571.38 (+10.59%) |
Aug 25, 2026 5w ago | Insider Cluster | $516.68 $492.02 | ▼ −4.77% | ▼ −4.65% | $571.38 (+10.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access